Clinical Trial

Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease

Trial met primary endpoint with a statistically significant higher percentage of patients achieving a clinically meaningful cholestasis response compared to…

1 year ago

AVITA Medical Submits FDA PMA Supplement for RECELL GO

VALENCIA, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading…

1 year ago

Zenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for the treatment of NRG1+ pancreatic cancer

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 29, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company…

1 year ago

Celularity Announces Presentation at Upcoming 7th International Conference on Orthopedics

Data will be presented from an in vitro study of decellularized-flowable placental connective tissue matrix supporting cellular functions of human…

1 year ago

Zymeworks Appoints New Director

VANCOUVER, British Columbia, June 29, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional…

1 year ago

Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer

SAN FRANCISCO, June 29, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Sasha Damouni…

1 year ago

Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment

Submitted NDA for Libervant™ (diazepam) Buccal Film for treatment of seizure clusters in patients between two and five years of…

1 year ago

NeuBase Presents Non-Human Primate Data Illustrating Stealth Editors™ are Non-Immunogenic, Opening the Door to Redosing

New preclinical data validates that Stealth Editors™ are non-immunogenic, as featured in a poster presentation at the 28th American Peptide…

1 year ago

Microbot Medical Successfully Completes an Extensive Pre-Clinical Study Performed in the US

The study was conducted over two days by a team of global key opinion leaders and with participation of executives…

1 year ago

Pasithea Therapeutics Announces Completion of GMP Manufacturing for PAS-004

-- Represents the final step before submission of Investigational New Drug (IND) application to FDA, expected in the second half…

1 year ago